Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J García-Donas

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Revista Clinica Espanola|July 28, 2004
[Non surgical pneumoperitoneum]F Moreno Antón, J García-Donas
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable diseaseC Jara Sánchez, C Olier Gárate, J García-Donas Jiménez, et al.
Archivos De Bronconeumologia|June 20, 2001
[Recurrent pneumonia secondary to idiopathic bronchomalacia]J García-Donas Jiménez, M J Núñez Orantos, J M Fernández Sánchez-Alarcos, et al.
The Pharmacogenomics Journal|January 27, 2016
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinomaM H Diekstra, A Belaustegui, J J Swen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2023
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201A Necchi, D Pouessel, R Leibowitz, et al.
The Pharmacogenomics Journal|March 10, 2010
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicityS Leskelä, C Jara, L J Leandro-García, et al.
Histology and Histopathology|December 13, 2012
Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray studyI Muñoz-Repeto, M J García, M Kamieniak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
British Journal of Cancer|April 6, 2013
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomasM M Kamieniak, I Muñoz-Repeto, D Rico, et al.
ESMO Open|April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapyE Grande, T Alonso-Gordoa, O Reig, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Revista Clinica Espanola|July 28, 2004
[Non surgical pneumoperitoneum]F Moreno Antón, J García-Donas
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable diseaseC Jara Sánchez, C Olier Gárate, J García-Donas Jiménez, et al.
Archivos De Bronconeumologia|June 20, 2001
[Recurrent pneumonia secondary to idiopathic bronchomalacia]J García-Donas Jiménez, M J Núñez Orantos, J M Fernández Sánchez-Alarcos, et al.
The Pharmacogenomics Journal|January 27, 2016
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinomaM H Diekstra, A Belaustegui, J J Swen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2023
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201A Necchi, D Pouessel, R Leibowitz, et al.
The Pharmacogenomics Journal|March 10, 2010
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicityS Leskelä, C Jara, L J Leandro-García, et al.
Histology and Histopathology|December 13, 2012
Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray studyI Muñoz-Repeto, M J García, M Kamieniak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
British Journal of Cancer|April 6, 2013
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomasM M Kamieniak, I Muñoz-Repeto, D Rico, et al.
ESMO Open|April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapyE Grande, T Alonso-Gordoa, O Reig, et al.
Pageof 2